Deucravacitinib at EULAR 2022

  • Dr. Peter Nash

Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on:

- Safety of Deucravacitinib https://bit.ly/3NtZQxe

- Deucravacitinib in SLE https://bit.ly/3Mh5nG0

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×